Logo for IVERIC bio Inc

IVERIC bio Investor Relations Material

Latest events

Logo for IVERIC bio Inc

Q4 2022

IVERIC bio
Logo for IVERIC bio

Q4 2022

1 Mar, 2023
Logo for IVERIC bio

Q3 2022

3 Nov, 2022
Access the full event backlog
Slides, Transcripts, and Reports from over 8,000 public companies
IVERIC bio Inc is a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene.